US co Amneal plans units in India for weight-loss drugs
Amneal Pharmaceuticals, the third largest generic drugmaker in the US, plans to invest $150-200 million over the next four to five years to build a manufacturing facility in Ahmedabad housing two greenfield plants for producing weight loss drugs.
Election Results Haryana Live
J and K Election Results Live
Haryana's political showdown revealed
The project will also feature investments from US biotech firm Metsera in addition to fiscal incentives from the Gujarat government.
«So, the total project size could reach up to $250 million to $300 million in the next four to five years,» Chirag Patel, president and co-CEO told ET.
One of the plants will be used for producing peptide synthesis, and the other for sterile fill-finish manufacturing. The new site broke ground on Tuesday.
«Phase one is 100 million capacity, and up to five tons of API...(our) preference is Metsara, obviously innovative side along with providing some capacity to the big guys like Novo Nordisk and Eli Lilly, right, and we will have our generic portfolio including generic GLP-1 going forward,» Patel said.
Marketing
Digital Marketing Masterclass by Pam Moore
By — Pam Moore, Digital Transformation and Social Media Expert
HR
Human Potential and the Future of Employment
By — Lynda Gratton, Prof. at London Business School, Speaker, Author, Global Thought Leader
Finance
Financial Reporting and Analytics
By — Dr. C.P. Gupta, Professor: Department of Finance and Business Economics, University of Delhi
Legal
Data Privacy with General Data
